The market report titled Ankylosing Spondylitis market has been recently added by Absolute Markets Insights to its extensive repository and the data can be used to gain penetrative insights into the businesses. The case study thus addresses the present market scenario and historical developments of the market. The global Ankylosing Spondylitis sector has been scrutinized with regards to key elements such as products or services, applications, end-users, and technologies. Moreover, the case study has been gauged on the basis of primary and secondary research methodologies. Furthermore, with the help of different analysis tools such as SWOT analysis and Porter’s five analysis accurate knowledge of Ankylosing Spondylitis market has been presented to readers. Graphical presentation techniques such as ample graph, tables, charts, and pictures further enhances the understanding of market data. The report has been created precisely by gauging intricate market aspects and presented to readers for an effective market study.
Additionally, the report presents extensive knowledge on distinctive market attributes such as production, revenue, and capacity. Among other distinctive features of the market report, it also includes coverage of influential market trends and of the current scenario on market shares. Significant information of the report is supported by evidence of prominent companies such as financial overview, specification and recent developments. Finally, the research also draws attention to possible strengths, weaknesses, threats, and opportunities that can affect the progress of global Ankylosing Spondylitis market.
Competitive Outlook: AbbVie Inc, Amgen Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi Aventis, CELGENE Corporation, Celltrion Healthcare Co., Ltd., Eisai Co., Ltd., Galapagos NV, Protalix Ltd., Regeneron Pharmaceuticals, Inc., Shanghai Pharmaceuticals Holding Co., Ltd, UCB S.A., and Xian Janssen Pharmaceutical Ltd amongst others.
Get Full Information of this premium report: https://www.absolutemarketsinsights.com/reports/Ankylosing-Spondylitis-Market-2018-2026-123
Management of ankylosing spondylitis can be done with pharmacological and nonpharmacological treatments. Pharmacological treatments are limited but however researchers are working on innovations in biological drugs and improvements of the treatment in this field. These treatments involve preservation of physical function, control of inflammation and symptoms and stoppage of progressive structural damage and disabilities. In pharmacological treatments, non-steroidal anti-inflammatory drugs (NSAIDs) can help to reduce the symptoms and signs of axial movements with spondyloarthropathies. In many studies it has been observed that, NSAIDs provide great and rapid relief to inflammatory back pain. However, with this treatment, several rebound symptoms such as stiffness, swelling and joint pain can be observed after few days. Nonpharmacological treatments for ankylosing spondylitis involves regular exercise and patient training. It has been observed that these treatments are helpful in enhancement of spinal mobility parameters however they have not affected disease activity.
The ankylosing spondylitis market, in terms of revenue, was valued at US$ 5.34 Bn in 2020 and is expected to reach US$ 6.84+ Bn by 2030.
Asia Pacific region represents a lot of opportunities for future growth in the market. The organizations and institutes in this region are investing heavily in R&D as there are not any approved treatments available for this disease. For instance, Novartis Pharmaceuticals in Japan is currently carrying clinical trial on patients for clinical efficacy and safety of secukinumab subcutaneous injections for the treatment of ankylosing spondylitis. The study was started in April 2016 and expected to complete in November 2018.
Ankylosing Spondylitis Market:
By Drug Type
Nonsteroidal Anti-Inflammatory Drugs
Others (IL-17 Inhibitors)
Middle East and Africa
Company: Absolute Markets Insights
Email id: [email protected]
Contact Name: Shreyas Tanna